Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CyberKnife MTD with Gemcitabine and nab-paclitaxel in Pancreatic Cancer
NCT02707328Phase 1Terminated
- Sponsor
- Cooper University Health Care
- Start
- Jan 2015
- Primary completion
- Nov 2017
- Countries
- 1
01
Overview
Phase 1, open-label trial in pancreatic adenocarcinoma (PDAC), sponsored by Cooper University Health Care. Primary endpoint: Maximum Tolerated Dose. Started Jan 2015; status: terminated.
02
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02707328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02707328.